Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Raloxifene

Drug Profile

Raloxifene

Alternative Names: Celvista; Evista; Keoxifene; LY 139481; LY 156758; Optruma; Sevista (raloxifene)

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Antineoplastics; Calcium regulators; Osteoporosis therapies; Small molecules; Stilbenes
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Breast cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Fracture; Postmenopausal osteoporosis
  • No development reported Cardiovascular disorders; Endometriosis; Hypercholesterolaemia; Leiomyoma; Vasomotor symptoms

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Apr 2014 Authorised generic raloxifene licensed to Prasco Laboratories in USA
  • 04 Mar 2014 First generic equivalent approved for Postmenopausal osteoporosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top